Metabolic manifestations of low-dose diuretics

American Journal of Medicine

Volumn 101, Issue 3 A, 1996, Pages 71S-82S

  Neutel, Joel M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; METOPROLOL; NICARDIPINE; NIFEDIPINE; PROPRANOLOL; THIAZIDE DIURETIC AGENT; VERAPAMIL; ANTIHYPERTENSIVE AGENT; BENZOTHIADIAZINE DERIVATIVE; DIURETIC AGENT; GLUCOSE; INSULIN; POTASSIUM;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; DIURETIC THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE UTILIZATION; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW; METABOLISM;

ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; DIURETICS; GLUCOSE; HUMANS; HYPERTENSION; INSULIN; LIPID METABOLISM; POTASSIUM; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0030606974     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00270-7     Document Type: Review

References (130)

1. Samuelsson OG, Wilhelmsen LW, Svardsudd KF, Pennert KM, Wedel H, Berglund GL. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: the study of men born in 1913 and the multifactorial primary prevention trial. J Hypertens. 1987;5:57-66.
2. Grimm RH Jr, Flack JM, Byington R, Bond G, Brugger S. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). Drugs. 1990;40:38-43.
3. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease. A review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(suppl 1):99-118.
4. Krotkiewski M, Mandroukas K, Sjostrom I, Sullivan L, Wetterqvist H, Bjorntorp P. Effects of long-term physical training on body fat, metabolism, and blood pressure in obesity. Metabolism. 1979;28:650-658.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
6. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-1520.
7. Weber MA, Smith DH, Neutel JM, Graettinger WF. Cardiovascular and metabolic characteristics of hypertension. Am J Med. 1991;91(suppl 1A):4S-10.
8. Neutel JM, Smith DH, Graettinger WF, Weber MA. Impact of a family history of hypertension on normotensive adults. Circulation. 1986;84:698.
9. Hjerman I, Helgeland A, Holme I, Lund-Larson PG, Leren P. The association between blood pressure and serum cholesterol in healthy men. The OSLO Study. J Epidemiol Community Health. 1978;32:117-123.
10. Anonymous. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events. Final report of the Pooling Project. J Chronic Dis. 1978;31:201-306.
11. Scannapieco G, Pauletta P, Pagnan A, et al. Lipoprotein binding to cultured aortic smooth muscle cells from normotensive and hypertensive rats. J Hypertens. 1988;6(suppl):S269-S271.
12. Jansen H. The mode of action of alpha 1 adrenoceptor blockers on blood lipids. J Human Hypertens. 1990;4:20.
13. Ferrara LA, Baggen MGA. Effects of doxazosin and propranolol administration of lipid lipases in cholesterol-fed rats. J Cardiovasc Pharmacol. 1987;10:S16.
14. Laakso M, Barrett-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis. 1989;9:665-672.
15. Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin dependent diabetic patients. Am J Epidemiol. 1989;130:632-645.
16. Al-Muhtaseb N, Al-Yusuf AR, Abdella N, Fenech F. Lipoproteins and apolipoproteins in young non-obese Arab women with NIDDM treated with insulin. Diabetes Care. 1989;12:325-331.
17. Niskanen L, Uusitupa M, Sarlund H, et al. Microalbuminuria predicts the development of serum lipoprotein abnormalities favoring atherogenesis in newly diagnosed type 2 (non-insulin dependent) diabetic patients. Diabetologia. 1990;33:237-243.
18. Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metab Clin Exp. 1988;37:982-987.
19. Abbott WGH, Lillioja S, Young AA, et al. Relationship between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes. 1987;36:897-904.
20. Neutel JM, Smith DH, Graettinger WF, Winer RL, Weber MA. Heredity and hypertension: impact on metabolic characteristics. Am Heart J. 1992;124:435-440.
21. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809-817.
22. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 1989;2:419-423.
23. Hunt SC, Stephenson SH, Hopkins PN, Hasstedt SJ, Williams RR. A prospective study of sodium-lithium countertransport and hypertension in Utah. Hypertension. 1991;17:1-7.
24. Laurenzi M, Trevisan M. Sodium-lithium countertransport and blood pressure: the Gubbio Population Study. Hypertension. 1989;13:408-415.
25. Trevisan M, Laurenzi M. Correlates of sodium-lithium countertransport. Findings from the Gubbio Epidemiological Study. The Gubbio Collaborative Study Group. Circulation. 1991;84:2011-2019.
26. Williams RR, Hunt SC, Hasstedt SJ, et al. Current knowledge regarding the genetics of human hypertension. J Hypertens. 1989:7(suppl 6)8-13.
27. Williams RR, Hunt SC, Hassted SJ, et al. Multigenic human hypertension: evidence for subtypes and hope for haplotypes. J Hypertens. 1990;8(suppl):S39-46.
28. Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension. 1992;19(suppl 1)78-82.
29. Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension. Lancet. 1987;ii:435-437.
30. Tuck M, Corry D, Trujillo A. Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Med. 1990;88:210-216.
31. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1991;15:861-866.
32. Meehan WP, Buchanan TA, Shargill NS, et al. Chronic insulin administration elevates blood pressure in rats. (Abstr.) Circulation. 1990;82:I11-86.
33. Hall JE, Coleman TG, Leland-Mizelle H. Dose chronic hyperinsulinemia cause hypertension. Am J Hypertens. 1989;2:171-173.
34. Hall JE, Coleman TG, Leland-Mizelle HL, Smith MJ Jr. Chronic hyperinsulinemia and blood pressure regulation. Am J Physiol. 1990;258:F722-F731.
35. Hall JE, Brands MW, Kivlighn SD, et al. Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines? Hypertension. 1990;15:519-527.
36. Brands MW, Mizelle HL, Gaillard CA, Hilderbrandt DA, Hall JE. The hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am J Hypertens. 1991;4:164-168.
37. Brands MW, Hildebrandt DA, Mizelle HL, Hall JE. Hypertension during chronic hyperinsulinemia in rats in not salt-sensitive. Hypertension. 1992;19:I83-I89.
38. Tsutsu N, Nunoi K, Kodama T, Nomiyama R, Iwase M, Fujischima M. Lack of association between blood pressure and insulin in patients with insulinoma. J Hypertens. 1990;8:479-482.
39. Sowers JR. Insulin resistance and hypertension. Mol Cell Endocrinol. 1990;74:C87-C89.
40. Feraille E, Krempf M, Charbonnel B, Bouhour JB, Nicolas G. Arterial hypertension in patients with obesity. Role of hyperinsulinism and insulin resistance. Revue de Medicine Interne. 1990;11:293-296.
41. Caro JF. Clinical review 26: insulin resistance in obese and non-obese men. J Clin Endocrinol Metab. 1991;73:691-695.
42. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertens. 1990;16:706-711.
43. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
44. Banskota NK, Taub R, Zellner K, Olsen P, King GL. Characterization of induction of protooncogene C-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-1. Diabetes. 1989;38:123-129.
45. Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest. 1968;18:538-551.
46. Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care. 1990;13:631-654.
47. Stout RW. Overview of the association between insulin and atherosclerosis. Metab Clin Exp. 1985;34(suppl 1):7-12.
48. Uusitupa Ml, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5 year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects. Circulation. 1990;82:27-36.
49. Fontbonne A, Tchobroutsky G, Eschwege E, Richards JL, Claude JR, Rosselin GE. Coronary heart disease mortality risk. Plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes. 1987;12:557-565.
50. Fontbonne A, Eschwege E. Diabetes, hyperglycemia, hyperinsulinemia and atherosclerosis: epidemiological data. Diabete Metab. 1987;13:350-353.
51. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policemen Study population. Acta Med Scand. 1985:701 (suppl):38-52.
52. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713-1724.
53. National High Blood Pressure Education Program Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153:186-208.
54. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens. 1991;9:465-473.
55. INTERSALT Cooperative Research Group. INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Br Med J. 1988;297:319-328.
56. Reed D, McGee D, Yano K, Hankin J. Diet, blood pressure, and multicollinearity. Hypertension. 1985;7:405-410.
57. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
58. Raison J, Bonithon KC, Egloff M, Ducimetiere P, Guy-Grand B. Hormonal influences on the relationship between body fatness, body fat distribution, lipids, lipoproteins, glucose and blood pressure in French working women. Arteriosclerosis. 1990;85:185-192.
59. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study. Int J Obes. 1986;10:229-240.
60. Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension. Role of insulin and catecholamines. Am J Hypertens. 1988;1:84-90.
61. Bonora E, Moghetti P, Zenere M, Tosi F, Travia D, Muggeo M. B cell secretion and insulin sensitivity in hypertensive and normotensive obese subjects. Int J Obes. 1990;14:735-742.
62. Laakso M, Sarlund H, Mykkanen L. Essential hypertension and insulin resistance in non-insulin-dependent diabetes. Eur J Clin Invest. 1989;19:518-526.
63. Sowers JR. The impact of diuretics on potassium and glucose. J Cardiovasc Pharmacol. 1984;6(suppl 3):S477-S482.
64. Weinberger MH. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med. 1985;145:1102-1105.
65. Samuel P, Kirkendall W, Shaefer EJ, et al. Effects on iradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension. Am J Cardiol. 1988;62:1068-1071.
66. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280-1288.
67. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
68. Kaplan NM. Effects of antihypertensive therapy on insulin resistance. Hypertens. 1992;19(suppl 1):I16-I18.
69. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cardiol. 1988;61:H53-H59.
70. Joint National Committee on detection, evaluation, and treatment of high blood pressure. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med. 1993;153:154-183.
71. Superko HR, Wood PD, Krauss RM. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. Am J Med. 1989;86:26.
72. Pool PE, Seagren SC, Sajel AF. Metabolic consequences of treating hypertension. Am J Hypertens. 1991;4:494S-502.
73. Lehtonen A. Long term effect of pindolol on plasma lipids, apoproteins A, blood glucose, and serum insulin levels. Int J Clin Pharmacol Ther Toxicol. 1984;22:269-272.
74. Fogari R, Lazzari P, Zoppi A, et al. The effects of celiprolol in the shortterm treatment of hypertensive patients with type 2 diabetes. Curr Ther Res Clin Exp. 1990;47:879-888.
75. Day JL, Metcalfe J, Simpson CN, Lowenthal L. Adrenergic mechanisms in the control of plasma lipids in man. Am J Med. 1984;76:94-96.
76. Miller NE. Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am J Cardiol. 1987;60:17E-23.
77. Lijnen P. Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins. Am Heart J. 1992;124:549-556.
78. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycemic effect on hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet. 1985;i:123-126.
79. Loaldi A, Montorsi P, Fabbiocchi F, et al. Angiographic evaluation of coronary atherosclerosis in patients receiving propranolol. A two year follow-up. Chest. 1991;99:1238-1242.
80. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectors. Am J Cardiol. 1989; 64:433-439.
81. Levy J, Zemel MB, Sowers JR. Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med. 1989;87(suppl 6A);7S-16.
82. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31:415-420.
83. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J. Treatment of mild hypertension study (TOMHS). Final results. JAMA. 1993;270:713-724.
84. Fujii S, Matsumura S, Nakayama H, et al. Effect of long-term treatment with slow-release nifedipine on glucose homeostasis in hypertensive-diabetic patients. Jpn Pharmacol Ther. 1990;18:263-269.
85. Kazumi T, Yoshino G, Okutani T, et al. Plasma lipoprotein and apolipoprotein concentrations and glycemic control during short-term treatment with nifedipine in hypertensive patients with type II diabetes mellitus. Curr Ther Res Clin Ex. 1989;46:951-958.
86. Strunge P, Engby B, Schmidt E, Trostnann AF. Variation of serum lipoproteins in postmyocardial infarction patients treated with verapamil or placebo. Acta Med Scand. 1984;481(suppl):53-57.
87. Pool PE, Heron JM, Rosenblatt S, et al. Metabolic effects on antihypertensive therapy with a calcium antagonist. Am J Cardiol. 1988;62: 109G-113.
88. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol. Results from a randomized, double-blind study with parallel groups. J Hypertens. 1989;7:551-559.
89. Pezzarossa A, Cimicchi MC, Orlandi N, et al. Lack of effect of nicardipine and diltiazem on glucose and arginine-induced insulin release in obese subjects. Cardiovasc Drugs Ther. 1988;2:669-672.
90. Pasanisi F, Vaccaro O, Ferrara AL, et al. Effect of nicardipine on insulin secretion, glucose and lipid metabolism in hypertensive, non-insulin dependent diabetics. Eur J Clin Pharmacol. 1989;36:1-4.
91. Klauser R, Speiser P, Gisinger C, Schernthalner G, Prager R. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J Cardiovasc Pharmacol. 1990;15(suppl 1):S93-96.
92. Klauser R, Prager R, Gaube S, et al. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension. 1991;17:15-21.
93. Lundgren H, Bengtsson C, Lapidus L, Bengtsson L. Antihypertensive drugs and glucose metabolism. Comparison between a diuretic, a beta blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes. J Intern Med. 1990;228:597-602.
94. Rett K, Lotz N, Wicklmayr M, et al. Improved insulin action by ACE inhibition in type II diabetics. Dtsch Med Wochenschr. 1988;113:243-249.
95. Torlone E, Rambotti AM, Perriello G, et al. ACE inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia. 1991;34:119-125.
96. Whitcroft IA, Thomas JM, Rawsthorne A, Wilkinson N, Thompson H. Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics. Horm Metab Res. 1990;22(suppl):42-46.
97. Seefeldt T, Orskov L, Mengel A. Lack of effects of angiotensin converting enzyme (ACE) inhibitors on glucose metabolism in type 1 diabetes and arterial hypertension. Diabet Med 1990;7:700-704.
98. Shionoiri H, Ueda SI, Goroh E, Ito T, Ogihara T. Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J Cardiovasc Pharmacol. 1990;16:905-909.
99. Shionoiri H, Sugimoto KHJ, Minamisawa K, et al. Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. J Cardiovasc Pharmacol. 1990; 15:933-938.
100. Paolisso G, Gambardella A, Verza M, D'Amorc A, Sgambado S, Varricchio M. ACE inhibition improves insulin sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens. 1992;6:175-179.
101. Ames RP, Hill P. Increase in serum lipids during treatment of hypertension with chlorthalidone. Lancet. 1976;i:721-723.
102. Lehtonen A, Gordin A. Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. Eur J Clin Pharmacol. 1984;27:153-157.
103. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of diuretics on lipid metabolism in patients with essential hypertension. Angiology. 1976;27:707-711.
104. van Brummelen P, Gevers Leuven JA, van Gent CM. Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL cholesterol in patients with essential hypertension. Curr Med Res Opin. 1979;6:24-29.
105. Glueck Z, Weidmann P, Mordasini R, et al. Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone. Metabol Clin Exper. 1980;29:240-245.
106. Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52-66.
107. Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. The relationship between diuretics and serum cholesterol in hypertension detection follow-up participants. Am J Prev Med. 1986;2:248-255.
108. Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs. 1988;35(suppl 6):118-134.
109. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med. 1991;91(suppl 1A):11S-21.
110. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol. 1991;67:26B-35.
111. Boehringer K, Weidmann P, Mordasini R, Schiffl H, Bachmann C, Riesen W. Menopause-dependent plasma lipoprotein alterations in diuretic treated woman. Ann Intern Med. 1982;97:206-209.
112. Kovanen PT, Brown MS, Goldstein JL. Increased binding of low density lipoprotein to liver membranes from rats treated with 17-alpha-ethinyl estradiol. J Biol Chem. 1979;254:1367-1373.
113. Sowers JR. Metabolic changes associated with isradipine and hydrochlorothiazide in MIDAS: effects on serum cations and uric acid. In: Godfraind T et al, eds. Pharmacological Control of Calcium and Potassium Homeostasis. Dordrecht, Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1995:185-195.
114. McKenney JM, Goodman RP, Wright JT Jr, Rifai N, Aycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins. Pharmacotherapy. 1986;6:179-184.
115. Bielmann P, Leduc G. Effects of metoprolol and propranolol on lipid metabolism. Int J Clin Pharmacol Biopharm. 1979;17:378-382.
116. Freis ED. Critique of the clinical importance of diuretic-induced hyokalemia and elevated cholesterol level. Arch Intern Med 1989;149:2640-1648.
117. Fernandez M, Madero R, Gonzalez D, Camacho P, Villalpando J, Arriaga J. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertens. 1994;23:I-207-210.
118. Mersey J, D'Hemecourt P, Blaze K. Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension. Curr Ther Res. 1993;53:502-512.
119. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8:461-466.
120. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461-1468.
121. Berglund G, Andersson O. Low doses of hydrochlorothiazide in hypertension: antihypertensive and metabolic effects. Eur J Clin Pharmacol. 1976;10:177-182.
122. Beermann B, Groschinsky-Grind M. Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug. Eur J Clin Pharmacol. 1978;13:195-201.
123. Rosenthal T, Grossman E, Rathaus M, et al. Treatment of hypertension by enalapril and hydrochlorothiazide separately and together: a multicenter study. Israel J Med Sci. 1990;26:63-66
124. Hart W. Lisinopril-hydrochlorothiazide combination compared with the monocomponents in elderly hypertensive patients. J Hum Hypertens. 1991;5:85-89.
125. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Intern Arch Med. 1994;154:737-743.
126. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278-285.
127. Lang H. The results of a large multicentre study comparing low-dose lisinopril-hydrochlorothiazide with the monocomponents. J Hum Hypertens. 1991;5:73-76.
128. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens. 1993;11:217-221.
129. Canter D, Frank GJ, Knapp LE, et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens. 1994;8:155-162.
130. Romero R, Castellote E, Ocón J, Wagner B. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol. 1995;26:114-118.